Biotech
Grin Therapeutics
Grin Therapeutics raises $140M Series D at $700M valuation
$140M
Total Raised
Series D
Latest Round
2018
Founded
90+
Employees
New York, NY
1 min read
Quick Facts
Valuation
$700M
Latest Round Size
$140M
Latest Round Date
May 2024
Grin Therapeutics: Series D Funding Round
Grin Therapeutics has successfully raised $140M in Series D funding, reaching a valuation of $700M.
Company Overview
Developer of therapies treating serious neurodevelopmental disorders
Funding Details
The Series D round was led by Fidelity, with participation from Viking Global.
Company Information
- Headquarters: New York, NY
- Founded: 2018
- Employees: 90+
- Category: Biotech
Investment
Grin Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Fidelity: Verified investor in Series D
- Viking Global: Verified investor in Series D
Key Investors
Fidelity
Lead Investor
Verified investor in Series D
Viking Global
Investor
Verified investor in Series D
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Torl Biotherapeutics
Torl Biotherapeutics raises $96M Series C at $500M valuation
Torl Biotherapeutics raises $96M in Series C at $500M valuation. Antibody-based immunotherapies for cancer patients...
Editorial Team
Oct 10, 2025
1 min read•$96M
Biotech
Nilo Therapeutics
Nilo Therapeutics raises $101M Series A at $450M valuation
Nilo Therapeutics raises $101M in Series A at $450M valuation. Developing therapies based on neuro-immunology research...
Editorial Team
Oct 9, 2025
1 min read•$101M
Biotech
Arthrosi Therapeutics
Arthrosi Therapeutics raises $153M Series E at $800M valuation
Arthrosi Therapeutics raises $153M in Series E at $800M valuation. Developing next-generation gout treatment drug for chronic conditions...
Editorial Team
Oct 8, 2025
1 min read•$153M